Ad Hoc Announcement Pursuant to Art. 53 LR
GENEVA, Switzerland, November 11, 2026 — Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing novel small-molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, has closed a $105 million Series B financing led by a syndicate of leading life science investors.
Addex did not participate in the financing. Following the transaction, Addex retains an 8.5% equity interest in Neurosterix, representing a valuation of $18.6 million.
The financing proceeds will primarily support the planned Phase 2 clinical development of NTX-253, a highly selective muscarinic M4 positive allosteric modulator (PAM) being developed for schizophrenia. The funds will also support the advancement of Neurosterix’s broader pipeline of selective allosteric modulators targeting several neuropsychiatric disorders.
“The closing of this significant financing is a huge endorsement of the allosteric approach pioneered by Addex in schizophrenia as well as other neuropsychiatric disorders. Congratulations to the whole Neurosterix team, which has made enormous strides in advancing lead program NTX-253 through clinical development and ready for Phase 2, following our spin-out in 2024,” said Tim Dyer, CEO of Addex.
About NTX-253 and M4 PAMs
The M4 muscarinic receptor is a validated therapeutic target for schizophrenia and related disorders through the indirect modulation of dopamine signaling. NTX-253 is a potent, highly selective oral M4 PAM designed to fine-tune muscarinic signaling in the brain. This approach has the potential to reduce psychosis symptoms while avoiding movement disorders and metabolic complications associated with traditional dopamine antagonists.
Neurosterix has completed Phase 1 single-ascending-dose and multiple-ascending-dose clinical studies of NTX-253. The resulting data support the advancement of the candidate into larger Phase 2 clinical studies.
About Neurosterix
Neurosterix is a clinical-stage biotechnology company focused on advancing neuropsychiatric care through selective allosteric modulation. Its approach is designed to fine-tune brain signaling with greater precision and selectivity, with the goal of developing safer and more effective treatments for people living with schizophrenia, mood disorders and anxiety disorders.
The company’s pipeline includes:
- NTX-253: A selective muscarinic M4 positive allosteric modulator (PAM) being developed for schizophrenia.
- NTX-819: A potentially first-in-class mGlu7 negative allosteric modulator (NAM) targeting mood and anxiety disorders.
- NTX-529: A second differentiated M4 PAM being developed for additional psychosis- and mood-related disorders.
Neurosterix operates in Boston and Geneva. For more information, visit www.neurosterix.com.
About Addex Therapeutics
Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small-molecule allosteric modulators for neurological disorders.
Its lead drug candidate, dipraglurant, an mGlu5 negative allosteric modulator (NAM), is being evaluated for potential future development in brain injury recovery, including recovery following stroke and traumatic brain injury. Addex has also selected a GABAB PAM drug candidate for development in substance use disorders and successfully completed IND-enabling studies. In addition, the company is advancing a differentiated GABAB PAM compound for the treatment of chronic cough.
Addex holds an 8.5% equity interest in Neurosterix US Holdings LLC, a private spin-out company advancing a portfolio of allosteric modulator programs. These include an M4 PAM for schizophrenia, psychosis and mood-related disorders, and an mGlu7 NAM for mood disorders. Addex has also invested in Stalicla, a private Swiss company developing a precision medicine approach for neurodevelopmental and neuropsychiatric disorders.
Addex shares are listed on the SIX Swiss Exchange, while American Depositary Shares representing its shares are listed on the Nasdaq Capital Market. Both securities trade under the ticker symbol “ADXN.”
For more information, visit www.addextherapeutics.com.
Contacts
Tim Dyer
Chief Executive Officer
Telephone: +41 22 884 15 55
[email protected]
Mike Sinclair
Partner, Halsin Partners
Telephone: +44 (0)7968 022075
[email protected]
Addex Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the intended use of proceeds from the financing. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Forward-looking statements are based on management’s current expectations and beliefs and are subject to risks, uncertainties and important factors that could cause actual events or results to differ materially from those expressed or implied. These factors include, without limitation, uncertainties relating to market conditions.
These and other risks and uncertainties are described in greater detail under the section titled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, its prospectus and other filings that Addex Therapeutics may make with the U.S. Securities and Exchange Commission (SEC) in the future.
Any forward-looking statements in this press release represent Addex Therapeutics’ views only as of the date of this announcement and should not be relied upon as representing its views at any subsequent date. Addex Therapeutics expressly disclaims any obligation to update forward-looking statements.
